Iodine-123-iodobenzamide binding in Parkinsonism: Reduction by dopamine agonists but not L-Dopa

Journal of Nuclear Medicine

Volumn 37, Issue 7, 1996, Pages 1112-1115

  Schwarz, Johannes ^a   Oertel, Wolfgang H ^b   Tatsch, Klaus ^b  

^a UNIVERSITY OF ULM   (Germany)

^b NONE

Author keywords

diagnosis; dopamine agonist; iodine 123 iodobenz amide; L Dopa; Parkinson's disease; SPECT

Indexed keywords

BROMOCRIPTINE; DOPAMINE 2 RECEPTOR; IODINE 123; LEVODOPA; LISURIDE; PRAMIPEXOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DRUG BINDING; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; ISOTOPE LABELING; MALE; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIPARKINSON AGENTS; BENZAMIDES; BRAIN; CASE-CONTROL STUDIES; CONTRAST MEDIA; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; HUMANS; LEVODOPA; MIDDLE AGED; PARKINSON DISEASE; PROSPECTIVE STUDIES; PYRROLIDINES; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0029737550     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Schwarz J, Tatsch K, Arnold G, et al. Iodine-123-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with "de novo" parkinsonism. Neurology 1992;42:556-561.
2. Quinn N. Multiple system atrophy: the nature of the beast. J Neurol Neurosurg Psychiatry 1989;52(suppl):78-89.
3. 123I]IBZM SPECT. J Neurol Neurosurg Psychiatry 1994;57:1047-1056.
4. 123I]IBZM single-photon emission computed tomography. Arch Neurol 1993;50:513-516.
5. Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy: an analysis of 100 cases. Brain 1994;117:835-845.
6. Brücke T, Podreka I, Angelberger P, et al. Imaging of dopamine D2 receptors with SPECT: studies in patients with extrapyramidal disorders and under neuroleptic treatment. J Cereb Blood Flow Metab 1991;11:220-228.
7. 11C-raclopride and positron emission tomography. Ann Neurol 1992; 31:184-192.
8. 123I]IBZM SPECT. Mov Disord 1993;8:453-458.
9. Antonini A, Schwarz J, Oertel WH, Beer HF, Madeja UD, Leenders KL. Carbon-11-raclopride positron emission tomography in previously untreated patients with Parkinson's disease: influence of L-Dopa and lisuride therapy on striatal dopamine D2 receptors. Neurology 1994;44:1325-1329.
10. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52.
11. 123I]IBZM: initial experiences in controls and patients with Parkinson syndromes and Wilson's disease. Nucl Med Commun 1991;12:699-701.
12. Hughes AJ, Lees AJ, Stern GM. Challenge test to predict the dopaminergic response. Neurology 1991;41:1723-1725.
13. Gasser T, Schwarz J, Arnold G, Trenkwalder C, Oertel WH. Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson syndrome. Arch Neurol 1992;49:1131-1134.
14. Oertel WH, Gasser T, Trenkwalder C, Ippisch R, Poewe W. Apomorphine test for dopaminergic responsiveness. Lancet 1989;1:1262-1263.